Physiological characterization of an arginine vasopressin rat model of preeclampsia

Ramdin, Sapna; Naicker, Thajasvarie; Pillay, Virushka; Singh, Sima; Baijnath, Sooraj; Mkhwanazi, Blessing Nkazimulo; Govender, Nalini

doi:10.1080/19396368.2021.1981486

Cited by 9 publications

(10 citation statements)

References 83 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The infusion of AVP (200 ng/h) resulted in significantly elevated blood pressure and urinary protein, characterizing pre-eclampsia symptoms. Both systolic and diastolic blood pressures were elevated considerably throughout pregnancy in the PAVPS group in contrast to the PS group (Figure 1), similar to an earlier report from our lab (Ramdin et al, 2022), albeit at a lower dosage of 150 ng/h. The AVP-induced pre-eclamptic rats treated with hesperidin over 14 days significantly decreased blood pressure.…”

Section: Discussionsupporting

confidence: 89%

“…All rats received a dose of hesperidin or captopril (positive control) by oral gavage daily for 14 days from GD 7 to GD 20. The dosage of AVP and captopril was determined based on previous reports [30,31]. Systolic and diastolic blood pressure were measured on GD 7, 14, and 18 using the MRBP tail-cuff BP monitor (IITC Life Sciences Inc., USA) by placing animals in a suitably sized restrainer.…”

Section: Experimental Studymentioning

confidence: 99%

See 1 more Smart Citation

Hesperidin improves physiological outcomes in an arginine vasopressin rat model of pre‐eclampsia

Reddy,

Baijnath,

Singh

et al. 2023

Fundamemntal Clinical Pharma

Self Cite

View full text Add to dashboard Cite

BackgroundHesperidin, a flavanone commonly found in citrus fruits and herbal formulations, has emerged as a potential new therapeutic agent for modulating several diseases. Since pre‐eclampsia is a growing public health threat, it may negatively impact the economy and increase the disease burden of South Africa. Phytocompounds are easily accessible, demonstrate minimal side effects, and may confer novel medicinal options as a treatment and preventive preference.ObjectiveTo investigate the physiological, biochemical, and hematological outcomes of hesperidin in an arginine vasopressin (AVP)‐induced rodent model of pre‐eclampsia.MethodsFemale Sprague–Dawley rats were surgically implanted with mini‐osmotic pumps to deliver AVP (200 ng/h) subcutaneously. Animals were treated with hesperidin at 200 mg/kg.b.w via oral gavage for 14 days. Systolic and diastolic blood pressures were measured on GD 7, 14, and 18 using a non‐invasive tail‐cuff method and were euthanized on GD 21.ResultsThe findings showed that hesperidin administration significantly decreased blood pressure (P < 0.05) and urinary protein levels in pregnant rats (P < 0.001). Placental and individual pup weight also increased significantly in the pregnant hesperidin‐treated groups compared to AVP untreated groups (P < 0.001). Biochemical and hematological markers such as white blood cell count and lymphocyte levels differed significantly (P < 0.05) in AVP groups treated with and without hesperidin.ConclusionOur results suggest that hesperidin is an antihypertensive agent with modes of action associated with its diuretic and blood pressure lowering effects and reduction of proteinuria in AVP‐induced pre‐eclamptic rats.

show abstract

Section: Discussionsupporting

confidence: 89%

Section: Experimental Studymentioning

confidence: 99%

Hesperidin improves physiological outcomes in an arginine vasopressin rat model of pre‐eclampsia

Reddy,

Baijnath,

Singh

et al. 2023

Fundamemntal Clinical Pharma

Self Cite

View full text Add to dashboard Cite

show abstract

“…In addition, our laboratory has extrapolated the AVP mouse model of Santillan and co-workers to a Sprague Dawley rat model [ 128 ••]. Our findings demonstrate that chronic AVP infusion (150 ng/h) in pregnant rats over 18 days successfully reproduced the PE phenotype of elevated blood pressure (≥ 140/90 mmHg) [ 10 ], increased urinary protein levels, and fetal growth restriction.…”

Section: Rodent Models Of Pementioning

confidence: 73%

The Clinical Value of Rodent Models in Understanding Preeclampsia Development and Progression

et al. 2023

Self Cite

View full text Add to dashboard Cite

Purpose of Review Preeclampsia (PE) is a leading global cause of maternal and fetal morbidity and mortality. The heterogeneity of this disorder contributes to its elusive etiology. Due to the ethical constraints surrounding human studies, animal models provide a suitable alternative for investigation into PE pathogenesis and novel therapeutic strategies. The purpose of this review is to compare and contrast the various rodent models used to study PE, in order to demonstrate their value in investigating and identifying different characteristics of this disorder. Recent Findings Several approaches have been employed to create an appropriate animal model of PE, including surgical, genetic manipulation, and pharmacological methods in an attempt to mimic the maternal syndrome. Despite the absence of a model to completely model PE, these models have provided valuable information concerning various aspects of PE pathogenesis and novel therapeutic strategies and have led to the discovery of potential predictive markers of PE. Summary Rodent and murine models have contributed significantly to the study of the pathology associated with specific aspects of the disorder. As a single fully encompassing animal model of PE remains absent, the use of a combination of models has potential value in understanding its etiology as well as in new treatment and management strategies.

show abstract

“…Basic studies have supported the role of vasopressin in the pathogenesis of preeclampsia. Chronic low-dose AVP infusion in pregnant mice was able to induce the clinical phenotype of preeclampsia [8,20]. Additionally, AVP infusion throughout pregnancy in mice has been found to induce an elevation of pro-inflammatory interferon-gamma and cytokine interleukin (IL)-17, and a decrease of anti-inflammatory cytokine IL-4 [21], which was a typical immune imbalance encountered in preeclampsia [22,23].…”

Section: Discussionmentioning

confidence: 99%

“…Of multipathway involving in the pathogenesis of hypertension in pregnancy [6], the arginine vasopressin (AVP) pathway including AVP gene variation and AVP level may be one potential candidate. AVP (antidiuretic hormone) is a key player in maintaining fluid homeostasis, urine concentration, and pressure during pregnancy [7,8], whereas its excessive secretion may be a factor that initiates the development of hypertension in pregnancy [9]. Due to the short half-life (10-20 min) and extreme instability in vitro even stored in À208C plasma [10], the detection of AVP becomes intractable.…”

Section: Introductionmentioning

confidence: 99%

The relationship between arginine vasopressin gene polymorphisms and plasma copeptin and hypertensive disorders of pregnancy: a nested case-control study

Sun¹,

Guo²,

He³

et al. 2023

Journal of Hypertension

View full text Add to dashboard Cite

Objectives: This study aims to explore the relationship between polymorphism of the arginine vasopressin (AVP) gene and plasma copeptin concentration with the occurrence of hypertension in pregnancy. Methods:We conducted a matched nested case-control study in Chinese women. The genotypes of rs3729965, rs3761249, rs1410713, rs2740204, and rs2282018 loci of AVP gene and plasma copeptin at 16-20 gestational weeks were detected in 288 patients with gestational hypertension (GH), 82 with preeclampsia (PE), and 14 with chronic hypertension with superimposed preeclampsia (CH-PE) and their healthy matched controls.Results: For every natural logarithm unit increment in copeptin, the risks of GH and PE/CH-PE increased by 5.556 (adjusted odds ratio [aOR]: 6.556, 95% confidence interval [CI]: 2.734-15.717) and 3.312 times (aOR: 4.312, 95% CI: 1.168-15.914). Under the dominant model, the genotype CC R CT of rs2282018 and GG R GT of rs3761249 had higher risks of GH than genotype TT, with aORs of 1.757 (95% CI: 1.077-2.867) and 1.814 (95% CI: 1.111-2.963). Allele A of rs3729965 loci had a lower risk of PE/ CH-PE than allele G (aOR: 0.441, 95% CI: 0.199-0.978). However, the frequencies of rs1410713 and rs2740204 genotypes were not significantly different between cases and controls. The model of copeptin combined with the AVP gene and traditional factors (TFs) had a higher ability than the TFs model in predicting GH and PE/CH-PE. Conclusion:Our study confirms that higher plasma copeptin and AVP gene variants are associated with the occurrence of GH and PE/CH-PE. The detection of copeptin and AVP gene in the early second trimester improves the predictive ability of TFs for GH and PE/CH-PE.

show abstract

Physiological characterization of an arginine vasopressin rat model of preeclampsia

Cited by 9 publications

References 83 publications

Hesperidin improves physiological outcomes in an arginine vasopressin rat model of pre‐eclampsia

Hesperidin improves physiological outcomes in an arginine vasopressin rat model of pre‐eclampsia

The Clinical Value of Rodent Models in Understanding Preeclampsia Development and Progression

The relationship between arginine vasopressin gene polymorphisms and plasma copeptin and hypertensive disorders of pregnancy: a nested case-control study

Contact Info

Product

Resources

About